Market Overview

23andMe to Discontinue Access to Health-Related Genetic Tests During FDA Regulatory Review

Related GOOG
The FANG's Q2: A Sell-Side Preview
Nomura Bullish on Alphabet, Facebook, Spotify: 'Still Some Room For Growth'
Are You Ready For Alphabet's Q2 Earnings? (Seeking Alpha)

23andMe today announced that it will comply immediately with the U.S. Food and Drug Administration's directive to discontinue consumer access to its health-related genetic tests during the ongoing regulatory review process. The company will continue to provide consumers both ancestry-related information and raw genetic data without interpretation. In addition, the company will continue to conduct research using its database of genetic and phenotypic data, and also will continue its educational efforts.

See full press release

Posted-In: News Guidance FDA Management Global


Related Articles (GOOG)

View Comments and Join the Discussion!